NantOmics
| Company type | Limited liability |
|---|---|
| Industry | Biotechnology, molecular diagnostics |
| Founded | 2013 |
| Founder | Patrick Soon-Shiong |
| Headquarters | , |
| Products | Molecular diagnostic products |
| Website | https://nantomics.com |
NantOmics is a biotechnology company based in Culver City, California, which provides molecular diagnostic products for personalized cancer treatment. It is part of the NantWorks network, a corporation consisting of different startups in the medical and health industry.[1]
History
[edit]NantOmics was founded in 2013 by billionaire Patrick Soon-Shiong. In 2015 NantOmics bought the cancer diagnostics company OncoPlex Dx.[2] In 2017 the company acquired the consumer genomics startup Genos.[3] Three years later, in 2020, NantOmics shutdown Genos.[4]
Products
[edit]GPS Cancer involves sequencing of the genome and RNA of tumor cells in comparison to normal cells from the same individual in order to develop personalized treatments.[5] About 327,000 cancer patients participated in a GPS cancer pilot project in 2017.[6]
References
[edit]- ^ "NantOmics, LLC: Private Company Information - Bloomberg". www.bloomberg.com. Retrieved 2018-03-30.[dead link]
- ^ "NantOmics Acquires OncoPlex Diagnostics, an Accredited Proteomics Diagnostic Laboratory". Retrieved 2018-03-30.
- ^ "Bio-IT World". www.bio-itworld.com. Retrieved 2018-03-30.
- ^ "NantOmics Shuts Down Genos Direct-to-Consumer Genomics Services". genomeweb.
- ^ "GPS Cancer Overview". GPS Cancer. Retrieved 2018-03-30.
- ^ "NantHealth Reports 16% Increase in 2017 First Quarter Total Net Revenue; SaaS Revenue Rose 11% and GPS Adoption Continues to Climb". Retrieved 2018-03-30.